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ScienceDirectOptogenetics has revolutionized neuroscience by providing
means to control cell signaling with spatiotemporal control in
discrete cell types. In this review, we summarize four major
classes of optical tools to manipulate neuromodulatory GPCR
signaling: opsins (including engineered chimeric receptors);
photoactivatable proteins; photopharmacology through
caging — photoswitchable molecules; fluorescent protein based
reporters and biosensors. Additionally, we highlight technologies
to utilize these tools in vitro and in vivo, including Cre dependent
viral vector expression and two-photon microscopy. These
emerging techniques targeting specific members of the GPCR
signaling pathway offer an expansive base for investigating
GPCR signaling in behavior and disease states, in addition to
paving a path to potential therapeutic developments.
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Introduction
G-protein coupled receptors (GPCRs) are critical for
neuromodulation. GPCRs modulate neuronal excitability
by signaling through the heterotrimeric G-protein fami-
lies (Gs, Gi/o, Gq G12/13, among others), which can couple
to channels or enzymes via direct beta-gamma subunit
interactions or amplify intracellular signaling pathways
(Figure 1). Gq couples to phospholipase C, cleaving
phosphatidylinositol into IP3 and diacylglycerol (DAG),
mobilizing the release of calcium from intracellular stores.
This is known to facilitate depolarization, in addition toCurrent Opinion in Pharmacology 2017, 32:56–70 synaptic release in terminals, also dependent on calcium.
Gi/o signaling via beta-gamma interactions positively reg-
ulates G-protein coupled inward rectifying potassium
channels (GIRKs) to hyperpolarize the cell, as well as
negatively couples to calcium channels to inhibit synaptic
release. Gs signaling utilizes coupling to adenylyl cyclase
to amplify the levels of cAMP in a neuron, which can
influence excitability through cyclic-gated nucleotide
channels (CNGA2) or via enzymatic kinase mediated
pathways. GPCRs signal through other intracellular path-
ways through G-proteins and arrestin to modulate neuron
and glial activity independent of ionic changes in the cell.
Many neurotransmitters activate GPCRs that initiate in-
tracellular pathways with complex temporal and spatial
effects within a neuron. In the brain, cellular, receptor, and
signaling heterogeneity can cloud discrete conclusions.
Therefore, GPCR-based discoveries have slowly matured,
due to the intrinsic limitations of pharmacological manip-
ulations. These approaches lack both receptor subtype
specificity and cellular resolution. Though development
of optogenetics provided neuroscientists with the ability to
probe neural circuits with discrete spatiotemporal control,
most optogenetic applications have focused on using light-
sensitive ion channels. To achieve more naturalistic con-
trol of neuromodulator signaling, GPCR-based optoge-
netic and chemogenetic tools were created. These
techniques allow for the selective interrogation of specific
signaling and cell types in neural circuits with high spatial
and temporal resolution in vivo. These tools (used inde-
pendently or in a multiplexed fashion) offer powerful
means for neuromodulation in the brain.
Here we provide a description of recent advances in the
development of genetically targeted tools to interrogate
neuromodulation, more specifically GPCR signaling in the
brain (outlined in Table 1). This review is not meant to be
exhaustive; here we focus on recently developed
approaches used to characterize GPCR bias, or define
either specific endogenous GPCR intracellular pathways,
each with potential to be used in the brain to aid in the
development of novel therapeutic treatments. For more
comprehensive reviews, see Refs. [1–6]. We also compare
both optical and chemical techniques. Additionally, we
will discuss technological advancements for utilizing these
tools in vivo. Finally, we discuss future development and
application of optogenetic and chemogenetic tools.
Optogenetics: control or measurement of cell signaling
with light
Optogenetics describes the technology in which cells are
modified genetically to express light sensitive proteinswww.sciencedirect.com
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Schematic representations of GPCR signaling in neurons. (a) GPCRs
signal through both heterotrimeric G-proteins and arrestins. Gi
activates G protein-coupled inwardly-rectifying potassium channels
(GIRK) to hyperpolarize the cell and inhibits voltage gated calcium
channels (CaV2) to inhibit synaptic release. Gi and Gs respectively
inhibit or amplify cyclic AMP (cAMP) production. Gq couples to
phospholipase C to generate IP3 and DAG which in turn regulate
intracellular calcium stores. Arrestin signaling is predominantly
mediated through phosphorylation of MAP kinases. (b) Schematic
representation of Opto-b2AR depicting mutations for G-protein (Opto-
2AR-SS) or arrestin (Opto-b2AR-LYY) bias. (c) Schematic
representation of Designer Receptors Exclusively Activated by
Designer Drugs depicting mutations for G-protein (hM3D-Gq) or
arrestin (hM3D-Arr) bias. (IP3, Inositol triphiosphate; MAPK, mitogen
activated protein kinase).
Table 1
Recently developed optogenetic tools
Tool Mechanism 
Opsins [14,143] Conformational change 
Opto-Chimeras [1,20] Conformational change 
BLUF photoreceptors [35,37] Conformational change 
LOV domains [42,44,48] Proximity 
Conformational change 
Cryptochromes [3,51] Proximity 
Phytochromes [56,59,144] Conformational change 
Proximity 
Caged Ligands [145,146] Uncaging 
Photoswitchable molecules [4,67] Uncaging 
Photoswitchable tethered ligands [73,74] Uncaging 
Resonance Energy Transfer (RET) [75] Proximity, sensor 
Genetically encoded calcium indicators
(i.e. GCaMP) [5,82]
Sensor 
Fluorescent Protein Exchange (FPX) [80] Sensor 
www.sciencedirect.com allowing for either measuring or controlling cellular sig-
naling with light. Optogenetics debuted in neuroscience
as the direct activation of ion channels to regulate neuro-
nal excitability with discrete spatiotemporal control [7].
Current advances in optogenetics target specific members
of canonical GPCR signaling pathways with both natural
and engineered optically sensitive proteins. Additionally,
endogenous receptors are targeted by photoactivatable
ligands, a method called photopharmacology [4,8]. Fur-
thermore, other optogenetic approaches utilize genetical-
ly encoded reporters of protein-protein interactions or the
production of second messengers [9].
Opsins
Naturally occurring opsins
Opsins are photosensitive GPCRs bound to chromo-
phores. The first GPCR specific optogenetic tools were
naturally occurring opsins [10]. Animal opsins are advan-
tageous because they do not require exogenous chromo-
phores (called retinals) to be added to the brain. Naturally
occurring opsins are diverse in their spectral and signaling
properties, often requiring little mutation or special tun-
ing.
Vertebrate visual opsins: Visual opsins are conopsin and
rhodopsin, the latter is classified as a weak candidate for
optogenetics due to slow kinetics and bleaching. Con-
opsins have spectrally diverse excitation spectra. Devel-
oping tools from conopsin could in theory allow for the
combinatorial activation of two neuronal cell populations.
In the eye, conopsins couple to Ga transducin, part of the
Gi/o family of G-proteins, and thus optogenetic tools
based on conopsin will signal to Gi/o. Thus far, all humanTargeted pathway Activation Deactivation/
dissociation
G-protein and arrestin NIRW-UV Dark or bistable
G-protein and arrestin Red-blue Dark or bistable
Cyclic nucleotides Blue Dark
P13K Blue Dark
GTPase, MAPK Blue Dark
Kinase, GTPase, PI3K,
MAPK, transcription in vivo
Blue Dark
cAMP NIRW NIRW
ERK, PI3K, GTPase Red NIRW
GPCR UV Irreversible
GPCR, DAG UV (red) Green (blue)
GPCR UV Green
Kinase activity, 2nd
messengers, inter-and
intramolecular interactions
Red-blue Target protein
dependent
Calcium Red and
green
Calcium
dependent
Calcium, PIP2, PKA
activation, ERK activation
Red or
green
Target domain
dependent
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58 Neurosciencesconopsins have been characterized in neuronal cultures,
with some work in brain tissue [11]. The use of human
blue conopsin (vLWO; vertebrate long wavelength opsin)
and mouse red conopsin (vSWO; vertebrate short wave-
length opsin) for modulating neural circuits has been
validated brain slices [12]. Photostimulation of conopsin
modulates GIRK currents, a typical GPCR coupling
event in neural circuits. Additionally, unlike rhodopsin,
conopsins can be repeatedly activated without a notice-
able desensitization of the response [12]. Recently, con-
opsin hyperpolarized DRN neurons in brain slice, and a
chimera (see below) expressed in the DRN was able to
modulate anxiety behavior [12].
Melanopsin, a non-visual opsin, has also successfully
engaged neural circuits [13]. Melanopsins are activated
by blue light, but unlike the visual opsins, are bistable and
thus can be deactivated by yellow light. Though mela-
nopsin has the potential to couple Gi/o to regulate GIRK
channels in heterologous systems, when examined in
neurons it is almost exclusively Gq-coupled. Recently
two variants of melanopsin have been characterized for
transient and sustained Gq activation [14
]. Stimulation of
ectopic melanopsin in pyramidal neurons mimics Gq
modulation of channels [15].
Gs signaling can be activated by photo-stimulating certain
non-mammal opsins. Jellyfish opsin signals through Gs to
induce translocation of adenylyl cyclase, increase the
production of cAMP, and increase phosphorylation of
ERK [16]. A natural guanylyl cyclase fused to an opsin,
was recently discovered in fungus [17]. This cyclase,
termed Guanylyl Cyclase Rhodopsin (BeCyclOp), does
not produce cAMP, unlike previously engineered guany-
lyl cyclase optogenetic tools. BeCyclOp has a functional
spectrum broader than vertebrate opsins, with maximum
cGMP production in green (530 nm) light and low activity
in red and violet light. This cyclase was also functionally
expressed in Caenorhabditis elegans muscle cells, demon-
strating activity comparable to photo-stimulation from
channel-based optogenetics [18].
Opto-XRs
GPCR signaling in neural circuits may also be modulated
though intracellular signaling that may not be dependent
solely on generic Ga subunit coupling dynamics. There-
fore, to more closely mimic endogenous signaling, chi-
meric optogenetic tools have been engineered using
opsins with intracellular loops and C-terminal tail of
GPCRs endogenously expressed in the central nervous
system. The first of this family of ‘Opto-XRs’ were
adrenergic receptors Opto-a1AR and Opto-b2AR
(Figure 1b). [19,20]. The full profile of Opto-b2AR sig-
naling was recently validated as mimicry of most of the
endogenous receptor’s properties. This study was also the
first to express Opto-b2AR in vivo to demonstrate real
time behavioral responses in endogenous neural circuitsCurrent Opinion in Pharmacology 2017, 32:56–70 (anxiogenesis) [21,22]. Additionally, the first proto-
types of G-protein and arrestin biased chimeras have been
developed and characterized in vitro [21]. This study
reported diverse signaling dynamics were possible with
Opto-XRs mutated either in the canonical GPCR DRY
motif (Optob2-LYY, Addgene), known to be involved in
G-protein coupling [23], or in the c-terminal serines
(Optob2-SS, available in Addgene) known to be phos-
phorylation sites of G-protein coupled receptor kinase
(GRK; Figure 1b) [24]. These prototypes differed in
canonical ERK signaling, densensitization and internali-
zation patterns. However, future studies and additional
prototypes are warranted in this regard, as crystal struc-
tures, critical residues for G-protein and arrestin bias, and
interactions continue to be identified [25].
Another chimera, Opto-A2AR, from bovine rhodopsin
chimera and the Adenosine 2A receptor, was also charac-
terized in vitro and in vivo [26]. Opto-A2AR mimicked
endogenous A2AR by increasing cAMP production and
differentially recruiting phosphorylation of only CREB in
the hippocampus and only MAPK in the nucleus accum-
bens (NAc). In the same behavioral paradigm, stimulation
of Opto-A2AR in the hippocampus impaired memory
consolidation, while stimulation in the NAc did not affect
memory but increased locomotor activity. This demon-
strates that Opto-A2AR mimics differential A2A signaling
in endogenous brain regions which leads to also different
behaviors [26].
OMOR, comprised of rat rhodopsin with intracellular
components of the mu opioid receptor (MOR), mimics
endogenous opioid signaling in vitro through Gi/o protein
and arrestin mediated signaling, by inhibiting production
of cAMP, coupling to GIRK and stimulating ERK phos-
phorylation. In neuronal slices, saturating concentrations
of mu agonist, DAMGO, prevented a subsequent re-
sponse to photo-stimulation of OMOR-induced GIRK
currents suggesting this chimeric receptor accessed the
same intracellular pools of downstream effectors. Lastly,
OMOR also mimicked MOR’s ability to induce either a
preference or aversion depending on the endogenous
neural circuit where it was expressed [27]. This study
comprehensively validated the use of OMOR as a proxy
for MOR a variety of preparations.
Additional, chimeric GPCRs have been engineered with
melanopsin and conopsins and have been utilized in vivo
[12,15,28,29]. Opto-mGluR6, which is human melanop-
sin with the intracellular components of metabotropic
glutamate receptor mGluR6, was used to restore vision
through ON bipolar cells in blind mice [28]. Other non-
rhodopsin chimeras are partial chimeras that contain only
some of the intracellular domains serotonin receptors.
Herlitze and colleagues used the C-terminal tail of sero-
tonin receptors to target opsins to the appropriate signal-
ing domains. This method was also used to create toolswww.sciencedirect.com
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melanopsin (Gq coupled) with the c-tail of 5HT1A and
5-HT2C, respectively. Both tools modulated dorsal raphe
circuits involved in anxiety behavior. Recently, another
partial melanopsin–serotonin chimera, created only with
the intracellular loops of 5-HT2A, was reported to tran-
siently hyperpolarize cells, but unreliable expression
prevented quantification of the effects [15].
One exciting possibility with these chimeric Opto-XR
approaches is the ability to mimic spatial and temporal
properties of neuromodulator signaling at synapses or in
vivo. For example, tuning the amount of response via a
photo-stimulation event to mirror the release and acti-
vation kinetics of a monoamines or neuropeptides will
allow us to better understand how these signals are
transmitted in time, over small distances, in genetically
defined cell types, and neural circuits. In addition, future
approaches to define the 2-photon emission spectra of
these opsin tools will allow for more advanced imaging
studies in vitro in brain sections alongside sensing of
signal transduction (i.e. GCaMP, or FLIM-based meth-
ods; see below). This would allow the investigator to
perturb signaling in a native system while capturing
neuronal ensemble dynamics, or GPCR signaling in real
time. Advances along these avenues are likely to occur as
additional Opto-XRs and native GPCR opsins become
characterized and validated side-by-side against their
native receptor counterparts. Additional work will be
needed to validate the expression and localization  pro-
files of these non-native receptor tools, and they may not
recapitulate endogenous GPCR trafficking, and may
need chaperone sequences added in some cases. These
photo-sensitive GPCR constructs could also be used for
subcellular optogenetics to investigate bias based on
GPCR localization. Localization of signaling is now at
the forefront of GPCR research. Gautam et al. demon-
strated that Gbg subunits not only translocate to intra-
cellular membranes upon GPCR activation, but regulate
cytoplasmic calcium concentrations [30,31]. Additional-
ly, there is recent and increasing evidence for the sustain
propagation of G-protein-mediated signaling within
endosomes [32,33]. Photoactivatable proteins are anoth-
er powerful tool to investigate subcellular GPCR signal-
ing cascades.
Photoactivatable proteins
In addition to activation of GPCRs, there are other
optogenetic tools for the activation/inhibition of 2nd
messengers. This subset of tools includes unmodified
proteins and engineered/chimeric tools containing natu-
rally derived domains from non-mammalian species.
These tools regulate downstream signaling through two
mechanisms: allostery and proximity (Figure 2). For a
more comprehensive review of these tools, see Ref.
[3,34].www.sciencedirect.com Flavoproteins
Flavoproteins are a diverse set of proteins that contain
blue light sensing domains that use either flavin adenine
dinucleotide (FAD) and flavin mononucleotide (FMN)
chromophores, both produced in mammalian cells. These
include blue light using FAD (BLUF), light-oxygen-volt-
age (LOV) domains, and cryptochromes (Figure 2a). Fla-
voprotein domains used for optogenetic tools either
initiate enzymatic activity, dimerize, or change in confor-
mation, all in response to light.
Photoreceptors containing BLUF domains modulate cy-
clic nucleotide production (for a complete review on tools
to modulate cAMP signaling see Ref. [35]); Pioneering
studies used naturally derived flagellate Photoactivated
Adenylyl Cyclase (PACa) to modulate behavior in non-
mammalian model organisms [36–39]. Recently, investi-
gators used PAC in rodent neuronal cultures to define the
cAMP-PKA pathway that modulates axonal branching, a
study capitalizing on the subcellular spatiotemporal con-
trol of optogenetics [40]. BLUF domains are the primary
way to optogenetically manipulate cAMP aside from
GPCRs, though the precise mechanism of activation is
unknown. Excitingly, the crystal structure of a smaller
version of PAC was characterized from cyanobacteria
Oscillatoria acuminate (OaPAC), providing insights on its
mechanism of light activation [41].
LOV domains uniquely offer two mechanisms for tool
development, conformational change and dimerization
(for review see Ref. [42]). Light induced conformational
change in the AsLOV2 domain, includes the unfolding of
the Ja helix, which reveals the c-terminus [43]. In the
‘unmasking’ approach, enzymatic or binding domains are
fused to the c-terminus [42] (Figure 2a, upper left).
Unmasking was used to design a photoactivatable GTPase
(PA-Rac1), which was used in brain with some success
(NAc cocaine) [44,45]. Recently, AsLOV2 was also used as
the foundation for light-induced protein dissociation, an
approach called LOV2 trap and release of protein (LOV-
TRAP). The creators of LOVTRAP generated a small
protein (ZDark) with high affinity to the coiled Ja helix,
thus protein association only occurs in the dark. In the
proof of concept study, LOVTRAP was used to sequester
proteins from their signaling domain, but this approach
can be extended to diffusible partners [46]. Dimer
association can be achieved with the Vivid (VVD) LOV
domains that do not contain the Ja helix [47,48]. Recently,
VVD domains were tuned to create Magnets, a family of
photoswitches with dissociation constants ranging on the
time scale of seconds to minutes. The authors demon-
strated the utility of magnets by creating a photoactiva-
table phosphatidylinositol 3-kinase with the ability to
change the morphology of COS-7 cells [49].
Cryptochromes are another class of proteins able to create
dimers. CRY2-CIB1 heterodimers are widely used inCurrent Opinion in Pharmacology 2017, 32:56–70
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Schematics of Non-GPCR optogenetic tools (a) Blue light sensitive flavoproteins induce conformational changes (LOV and BLUF domains, left
panel) or protein interactions (LOV domains and cryptochromes, right panel) (b) Red sensitive phytochromes induce both conformational changes
(bacteriophytochromes, left panel) or photoswitchable protein interactions (plant phytochromes, right panel). (c) Photopharmacology techniques:
peptides may be caged by the addition of a photolabile carboxynitrobenzyl moiety (CNB) to tyrosine (top), or photoswitchable ligands provide
reversible caging through photoisomerization of azobenzene (bottom). (d) Ratiometric optogenetic reporters: FRET sensors report protein
interactions (top). GCaMP, is a genetically encoded calcium sensor (middle). Fluorescent Protein Exchange sensors rely on the change of affinity
of a fluorescence enhancing monomer (bottom). (AsLOV2, avena sativa phototropin 1 LOV domain; Bphy, Rhodobacter sphaeroides
bacteriophytochrome domain; CIB1, CRY-interacting bHLH1 (helix-loop-helix 1); CRY2, cryptochrome 2; CFP, cyan fluorescent protein; NIRW,
near infrared window; PIF, phytochrome interaction factor; PHY, phytochrome domain; YFP, yellow fluorescent protein).
Current Opinion in Pharmacology 2017, 32:56–70 www.sciencedirect.com
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and regulate protein localization [50,51]. CRY2-CIB1
technology was specifically used to inhibit G-protein
signaling by recruiting regulator of G-protein signaling
4 (RGS4) to the plasma membrane, providing both the
groundwork for tools to optically control G-protein acti-
vation with subcellular precision, and new insights into
GPCR localized signaling [52]. Interestingly, CRY2
domains also have the ability to form homodimers. This
has been used recently to develop CRY2olig: Light
Induced Co-clustering (LINC), which can be used as a
mode of activation or inhibition through sequestration.
Limitations to LINC are similar to those of co-immuno-
precipitation, for the binding partners of the target pro-
tein may be sequestered as well. Another consideration is
that oligomerization through LINC currently does not
have the capability to localize clustering to a specific
subcellular domain.
Phytochromes
Tools engineered with phytochromes enhance temporal
control of signaling because they are bistable; they are
sensitive to both red and neared infrared wavelengths of
light (650–750 nm). Near red wavelengths are ideal for in
vivo models due to the deceased amount of photo toxicity
and increase penetrance in tissue [53]. However, red-
shifted proteins do have the risk of thermal activation
[54]. Phytochromes are derived from plant, fungi and
bacteria; and like LOV domains they can regulate signal-
ing through conformational changes and dimerization
(Figure 2b).
Bacteriophytochromes are an extremely attractive plat-
form for in vivo applications since not only are they the
most sensitive to far red wavelengths, but their chromo-
phore (biliverdin) is present in all mammalian cells
[53,55]. Bacteriophytochromes are enzymatic photore-
ceptors. Though the exact details of conformational
changes that lead to the activation of bacteriophyto-
chromes is unknown, two groups have used crystal struc-
tures to engineer optogenetic tools to regulate cyclic
nucleotides in eukaryotic cells. Light-activatable phos-
phodiesterase (LAPD) was based on structure similarities
of the regulatory domains of human phosphodiesterase,
PDE2, and the light sensing domain of a bacteriophyto-
chrome histidine kinase, PaBPhy. Fusion of the phos-
phodiesterase and light sensitive domains of these
proteins generated a red light-activatable phosphodies-
terase that deactivates in far red light [56]. LAPD was
functional in whole zebrafish embryos, but has yet to be
used in a behavioral assay. Also guided by structure, Ryu
et al. [55] generated a near infrared window light activat-
ed adenylyl cyclase (Ilac) by fusing domains of a bacter-
iophytochrome diguanylate cyclase and bacterial adenylyl
cyclase. The authors used this tool to induce locomotion
in wildtype C. elegans through the production of cAMP, anwww.sciencedirect.com experiment not possible using PAC, due to confounding
blue light avoidance in wildtype in C. elegans [38,57].
Optogenetic tools derived from plant phytochromes take
advantage of the heterodimerization of the PHY domain
with PIF3 or PIF6 [58,59]. These domains can be used to
associate known interacting partners, or to translocate a
protein of interest to its functional intracellular domain.
Phytochrome heterodimers may be preferred over flavo-
proteins due to their red-shifted sensitivity; however, the
chromophore PCB is not endogenous in mammalian cells,
limiting its application in neuroscience. Additional genet-
ic engineering would be required to enable cells to
synthesize PCB [60]. Phytochromes have been used to
generate optogenetic tools for the regulation of phosphoi-
nositides and ERK [61,62]. It is likely that future itera-
tions of phytochrome domains will begin to be used in
cultured neurons and in brain tissue as they become
refined and more well accepted. Phytochromes offer
several advantages for dissecting subdomains of neuronal
signaling, and for uncovering the complexity of the in-
tracellular compartments involved in neuromodulation.
Photopharmacology
Studies using classic pharmacological approaches are
limited: drugs cannot target a subset of constitutively
expressed proteins with spatiotemporal precision. How-
ever, spatiotemporally precise drug delivery can be
achieved by integrating optical methods, an approach
called photopharmacology (Figure 2c). Photopharmacol-
ogy offers subcellular resolution while potentially pre-
serving properties of the native receptors, including
activation and deactivation kinetics, trafficking, and
levels of expression [63–65].
For several years, neuroscientists have practiced photo-
pharmacology with caged-ligands [66]. Caged ligands
contain a photosensitive moiety that render the ligand
inert. These ligands become biologically active only
milliseconds after UV photolysis. Recently, Banghart
and colleagues from the Sabatini group have used this
technology to target opioid receptors. Endogenous opioid
agonists were modified at the terminal tyrosine with a
photoactivatable chromophore. These ligands offered the
spatiotemporal control needed to study neuropeptide
signaling in brain tissue [64] (Figure 2c). In a later study,
the same group caged opioid antagonist naloxone to study
the deactivation kinetics of opioid signaling in vitro [65].
Though photo-caging is a powerful tool for delivering
ligands, it is largely irreversible in most instances. Re-
versible activation of ligands is achieved through the use
of proteins containing photolabile domains, also known as
photoswitches. The most common photoswitch is azo-
benzene, originally sensitive to UV light; red shifted
versions have developed to allow for use in vivo [67,68]
(Figure 2c). A photoswitchable small molecule mu opioidCurrent Opinion in Pharmacology 2017, 32:56–70
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approach [69]. Diffusible photoswitches have also been
developed to allosterically modulate metabotrophic gluta-
mate receptors [70,71]. Additional, neuropeptide photo-
ligand mimics are in development and offer exciting
extensions of this early work. These modified neuropep-
tides, however, have yet to be applied in vivo. Azobenzene
technology can also be extended to second messengers.
Recently, photoswitchable DAG was developed and used
to control synaptic transmission in hippocampal mouse
slices and C. elegans in vivo, illustrating the potential of
photoswitches to modulate specific signaling pathways
[72].
Diffusible photosensitive ligands allow for spatial acti-
vation, but, like traditional pharmacological methods,
lack genetic specificity. Genetic targeting can be
achieved with Photoswitchable tethered ligands
(PTL). PTLs are photosensitive ligands that will cova-
lently bind to an engineered protein [4]. This approach
was developed for metabotropic glutamate receptors
(LimGluR), but could be translated to another GPCRs
[73]. Although engineering GPCRs for PTL requires
minimal mutation, the design of PTLs entails modeling
based on crystal structures, possibly limiting their exten-
sion to less studied receptors [74]. Nevertheless, the
PTL approach is an attractive technology as minimal
mutations may preserve properties of the native receptor
and allow for integration of other mutations, including
those that generate bias.
Reporters
Not only can optogenetic approaches use light to induce
changes in the cell, they can also report localization,
intramolecular or intermolecular interactions, or the state
of the cell (voltage, pH, presence of second messengers)
(Figure 2d). These are usually fluorescent proteins (FP)
containing intrinsic chromophores. Optogenetic reporters
are useful for real-time imaging. Optogenetic reporters
are advantageous over chemical probes because through
mutagenesis their spectral properties can be changed.
Most commonly used are Resonance Energy Transfer
(RET) techniques. The RET approach examines inter
and intramolecular interactions by utilizing the overlap of
emission and excitation of light-emitting proteins [75]. In
this technique, light emitted from a donor protein excites
an acceptor FP within 100 A˚ [75]. The donor proteins of
RET are either bioluminescent (BRET), or fluorescent
[in the case of FRET (Fo¨rster Resonance Energy Trans-
fer)]. Interactions in RET are determined by analyzing
intensity. Classically, this is of the relative intensity
expressed as a ratiometric output, but RET can also be
determined by the exponential decay of the intensity of
the donor, fluorescent lifetime imaging (FLIM), which is
independent of relative protein expression [76]. Recent-
ly, a FRET-FLIM PKA sensor expressed in neurons wasCurrent Opinion in Pharmacology 2017, 32:56–70 able to report endogenous adenosine-A2A receptor activ-
ity, demonstrating the value of this technology to observe
GPCR signaling in the brain [77].
Other optogenetic reporters are comprised of single fluo-
rescent proteins. Previously, interacting domains of in-
terest were fused to independent halves of a single FP,
creating a fully functional protein based on proximity.
However, this approach is irreversible, posing challenges
for some applications. Alford and colleagues have devel-
oped a method using heterodimers: one monomer weakly
fluoresces due to a quenched chromophore; the second
monomer enhances the fluorescence (Figure 2d). Origi-
nally, there were two sets of AB heterodimers for either
red (RA and RB) or green (GA and GB) fluorescence
[78,79]. However, the enhancing partners (monomer B)
bound both RA and GA. Through optimization of the
monomer B, the authors created a sensor that would
fluoresce green or red depending on the preferential
affinity of monomer B, a concept coined Fluorescent
Protein Exchange (FPX) [80]. By fusing the monomers
to various protein domains, the author created sensors for
MAP kinase activity and a variety of second messengers
(Ca2+, PIP2, PKA activation via CaMP). Furthermore,
FPX sensors can be expressed single polypeptides, re-
ducing confounds of expressing multiple proteins.
Classically, Gq-mediated calcium increases via neuromo-
dulator receptors was detected by variety of dyes includ-
ing Fura-based compounds that cannot be targeted to
genetically defined neuronal populations. Recently, ge-
netically encoded calcium sensors (GECI) have revolu-
tionized neuroscience with the ability to detect calcium
transients as a proxy for action potential firing [5].
GCaMP-type GECIs are the most utilized and optimized
for in vivo applications, although in some cases they have
been used in primary cultures [81]. Reporters in the
GCaMP family are circularly permutated FPs fused to
calmodulin (CaM) and a Ca2+/calmodulin binding do-
main, M13 [82]. In the absence of Ca2+, the intrinsic
chromophore is exposed and therefore quenched by the
cytosol. In the presence of Ca2+, CaM and M13 interact,
protecting the chromophore from quenching, therefore
allowing the FP to fluoresce more effectively (Figure 2d)
[82]. The original GCaMP fluoresces green but now they
are available in other colors [83]. Though GCaMP has
been extensively used to uncover the specific contribu-
tions of neuronal ensembles to behavior or evoked circuit
activity, its value as a tool to investigate endogenous
GPCR signaling through pharmacological approaches is
only beginning to be realized [84]. In the next several
years, we are likely to see the use of this tool broadened
to neuromodulator based questions and in vivo drug
screening approaches. Developments in voltage indica-
tors such will also allow for fine temporal precision
of measuring neuromodulatory effects on membrane
potential [85,86].www.sciencedirect.com
Optogenetic tools for GPCR signaling in brain Spangler and Bruchas 63Chemogenetics: control of cell signaling with
biologically inert molecules
Chemogenetic tools allow for selective modulation of
GPCR signaling in specific tissues or cell types. Like
optogenetic tools, chemogenetic tools enhance the spa-
tial resolution of GPCR signaling; Chemogenetic tools
are also more easily adaptable for behavioral applica-
tions (Table 2). For a more extensive review on these
tools see Refs. [87–89]. The most widely used chemo-
genetic tools are modified GPCRs (see below). In addi-
tion to GPCRs, kinases have also been chemically
engineered. By mutating ATP-binding sites allowing
for the acceptance of bulky ATP analogues, Shokat and
colleagues were able to develop methods to selectively
inhibit kinase activity or identify substrates [90–92].
Both of these techniques have been used in neurosci-
ence applications, though not directly related to GPCRs
[93]. Mitogen activated protein kinases, commonly
downstream of both G-protein and arrestin signaling
pathways through GPCRs have also been a subject to
this engineering [94]. However, due to the toxicity of
thiophosphates, identification of kinase substrates has
limited use in vivo.Table 2
Comparison of optogenetic and chemogenetic tools
Tool Advantage 
Photoactivable
proteins
Microsecond temporal resolution [49] Costly equip
Subcellular Spatial resolution [52] Potential the
(long wavele
Abundant in nature [10] Phototoxicity
Diversity in wavelength and dynamic
range [144]
Less natural
High specificity of signaling
proteins/pathway
Invasive surg
Opto-XRs Receptor specific signaling Costly equip
Microsecond temporal resolution Chimeras 
Subcellular spatial resolution Invasive surg
Fine control of dosage Restrictive a
Diversity of tools
Greater potential for multiplexing
DREADDs Minimally modified Low tempora
Potential for chronic activation
over weeks [89]
Lower spatia
Minimal equipment required ‘Generic’ GP
Non-restrictive Lack of dive
Non-invasive stimulation Potential for
Many available transgenic lines [88] 
Pharmacolog
SalB: not wa
low KOR affi
CNO: can m
not complete
www.sciencedirect.com The pioneering chemogenetic GPCRs were termed
RASSLs, Receptor Activated Solely by Synthetic Li-
gands. RASSLs tended to have limited use in vivo, due
to either low affinity of RASSL ligands, endogenous
receptor activation, or constitutive activity [95]. The
newest generation of chemogenetic GPCRs, DREADDs
(Designer Receptors Exclusively Activated by Designer
Drugs), were designed to only respond to biologically inert
synthetic compounds [96]. Through directed molecular
evolution of the human muscarinic receptor, the Roth
group engineered a family of minimally mutated musca-
rinic receptors that are only activated by clozapine-N-
oxide (CNO), but not endogenous ligands, including
acetylecholine. Because of the diversity of muscarinic
receptors, DREADDs were originally either Gq (hM3Dq)
and Gi/o coupled (hM4Di) (Figure 1c).
Currently, hM3Dq and hM4Di are widely used in vivo to
excite and silence neuronal populations, and to modulate
gliotransmission [97–99]. Furthermore, the development
of DREADDs has been pivotal in selectively modulating
GPCR signaling specifically in the brain, notably signal-
ing through pathways that are not directly coupled toDisadvantage Mitigations
ment Spectral tuning
rmal activation
ngths) [54]
Use of 2-photon to reduce
phototoxicity [114]
 (short wavelength)
istic
ery
ment Newer devices to increase mobility
and minimize damage in behavior
[117]
Use of shorter wavelengths to
decrease phototoxicity and increase
penetrance
ery
ctuators
l resolution [89,97] Spatial resolution:
l resolution Use to target larger brain structure
[118]
CR signaling Target two pathways with one drug
[111]
rsity
 constitutive activity [123] Pharmacology:
Titration of CNO
ical limitations Alternative agonists for muscarinic
DREADDs available [109]
ter soluable and retains
nity [112]
etabolize into clozapine [108],
ly biologically inert [122]
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64 Neurosciencesexcitability through ionic changes. CNO-induced activa-
tion of hM3Dq has been validated in its mimicry of
acetylecholine-induced M3 receptor activation, aiding
in the development of an arrestin-biased and recent
Gq-biased DREADD, all of which have been character-
ized for use in vivo [100,101,102] (Figure 1c). Addition-
ally, hM4Di has the ability to inhibit vesicle release at
terminals, similar to endogenous Gi-coupled receptors in
the brain [99]. Thus, targeting hM4Di to axons offers a
tool to silence synapses, independent of the excitability of
the cell [103]. Unlike, hM3Dq and hM4di, Gs-coupled
DREADDs (rM3Ds) are chimeras, similar to Opto-b2AR,
except the extracellular domain is a Gq DREADD as
opposed to rhodopsin [104]. The value of DREADDs is
demonstrated by the discovery of novel PKA-dependent
GPCR signaling in consummatory behaviors. In an ex-
ploratory study, activation of rM3Ds in AgRP neurons
increased food intake, through activation of PKA [105].
Additionally, Gi-coupled postsynaptic receptors modulat-
ed binge alcohol behavior, through inhibition of PKA
signaling [106]. DREADDs have also been used to
elucidate sustained Gq-mediated neuronal inactivation
through JNK MAP kinase [107]. These experiments
highlight the ability of DREADDs to elucidate molecular
mechanisms of neuromodulation through G-protein acti-
vation.
Though DREADDs demonstrate cell behaviors akin to
endogenous GPCRs, their translational potential is limit-
ed by their ligands. Controversy over the metabolization
of CNO to pharmacologically active clozapine in humans
and guinea pigs inspired a structure-activity relationship
(SAR) analysis of DREADDs aimed to identify alterna-
tive agonists [108]. This study yielded ‘Compound 21’,
which is not metabolized in the same pathways as CNO,
eliminating the risk for conversion to clozapine [109].
This study also identified perlapine, a sleep-inducing
hypnotic drug, as a highly selective novel agonist for
hM3dq [110]. Lack of diversity in DREADDs and their
ligands, also limits the potential of multiplexing. Howev-
er, Alrdin-Kirk and colleagues took advantage of the
shared ligand by pairing hM3Dq and rM3Ds to maximally
activate dopamine neurons [111]. In addition to the Gq-
coupled excitation by hM3Dq, the inhibitory effects of
Gi-coupled dopamine autoreceptors were counteracted
by Gs signaling through rM3Ds. With these tools the
authors were able to define a cAMP induced mechanism
for Graft Induced Dyskinesia in Parkinsonian patients, a
phenomenon with no known mechanism and great clini-
cal relevance [111]. Alternatively, chemogenetic multi-
plexing can now be achieved with the use of KORD
(Kappa Opioid Receptor DREADD) [112]. KORD’s
design was driven by the structure of KOR combined
with molecular modeling of Salnorvin B (SalB), a low
affinity inert ligand of KOR. Because it is pharmacologi-
cally distinct, KORD can be used in concert with musca-
rinic DREADDs to gain bidirectional control of the sameCurrent Opinion in Pharmacology 2017, 32:56–70 neuron [111,112]. KORD is also kinetically unique from
hMD4i DREADDs, exerting shorter lasting effects.
KORD has played a pivotal role in expanding the che-
mogenetic toolbox for modulation of neural circuits.
Applicability of optogenetic and
chemogenetic tools
Optogenetic and chemogenetic tools have undoubtedly
revolutionized interrogation of specific GPCR signaling,
especially in the brain. Both genetic approaches have
inherent limitations; thus applicability of each toolset
depends on experimental design. It is important to note
that both approaches have been used to simulate the
endogenous signaling of the other techniques model
GPCRs: hMD3q has been used to recapitulate melanop-
sin signaling in the retina and melanopsin for muscarinic
signaling in pyramidal neurons of the cortex [15,113].
Optogenetics provides precise spatial (subcellular) and
temporal (microsecond) control of signaling. Temporal
control is enhanced with bistable tools (ligands, receptors,
effectors) that allow for inactivation by absorption at a
second wavelength. Because of the range of spectral
properties optogenetic tools from ultraviolet to near in-
frared wavelength, there is flexibility in the number of
available tools for a specific target. Additionally, since
photosensitive proteins are abundant in nature, there are
many unexplored avenues for tool development.
Currently, there are optogenetic tools available for each
step of the GPCR signaling pathway, from ligand binding
to downstream signaling events and deactivation. There
are some considerations in using optogenetics, although
recent advances in technology have addressed some of
these concerns. Biophysical considerations include the
risk of dark state activity, whether basal enzymatic activi-
ty, dimerization or incomplete caging, and limitations of
wavelength required for stimulation. Some opotogenetic
tools require blue or UV light, short wavelengths with
potentially toxic effects and shallow tissue penetration.
The use of UV light can be avoided either by delivering
two or more photons of lower energy, as in 2-photon
microscopy, a method especially useful for commonly
UV sensitive photoactivatable ligands. Two-photon mi-
croscopy also enhances the spatial resolution, as focusing
two beams restricts stimulation to a confined three di-
mensional space [114]. Furthermore, near IR wave-
lengths combined with cranial windows allow for the
stimulation and imaging of deep brain structures in vivo
[115]. Previously, in vivo actuators greatly limited behav-
ioral approaches because they were invasive, restrictive,
and lacked spatial precision. However, the latest optoge-
netic devices minimally damage the brain, liberate the
subject’s mobility and precisely deliver light [116,117].
Compared to optogenetics, chemogenetic approaches are
generally less technically challenging to use, for they arewww.sciencedirect.com
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genetic tools require no specialized equipment for actu-
ation; Because of its high blood brain barrier penetrance,
CNO can be administered through local or systemic
injection [99,103,118]. CNO is also water soluble, allow-
ing for chronic exposure through dilution in animal
drinking water for extended periods of time (i.e. 2 weeks),
without decreases in behavioral effects [89,119–121].
However, some recent studies highlight the need for care
and optimization when using DREADD receptors in vivo,
including the selection of proper control groups. Previous
concerns about the biological activity of CNO were
limited to only humans and guinea pigs, however a recent
study demonstrated that CNO also exerts behavioral
effects on rats that do not express DREADDs [122].
Another group also demonstrated biologically activity
of DREADDs in the absence of CNO [123]. These
studies highlight the importance of experimental design,
including proper controls.
Chemogenetic tools enable the activation of GPCR path-
ways with spatial resolution, though significantly less so
than optogenetic tools. Both tools can be similarly
expressed through stereotaxic injections (see below).
Optogenetics, however, allows for precise subcellular
stimulation of GPCR signaling, not available in chemo-
genetics [34]. Nevertheless, chemogenetic tools allow for
modulation of larger brain areas that cannot be feasibly
illuminated through optogenetic approaches [118]. Che-
mogenetic tools share limitations with classic pharmaco-
logical methods: these tools potentially have off-target
effects and lack precise temporal control. In addition to
the slower kinetics of activation, compared to optogenetic
tools, CNO has a slow wash out rate, potentially lasting for
at least a 2 hours [89,97,104]. Therefore, chemogenetics
are more suited for investigating slow, long-lasting be-
havioral effects. In summary, chemogenetic and optoge-
netic tools differ in their feasibility and spatiotemporal
resolution. Each toolset has a set potential strengths and
limitations, determined by experimental design. Both
tools can be used complimentary to each other to dissect
receptor specific from generic G-protein signaling [22].
Expression methods
The resolution of optogenetic and chemogenetic tools is
defined not only by stimulation but also expression.
These tools are expressed either virally or through trans-
genic animal approaches. Viral delivery is the most widely
used route for expressing transgenes [124]. Viral delivery
requires less commitment of resources needed to gener-
ate and maintain a genetic line. Additionally, viral ex-
pression is limited to the site of infection, increasing
spatial resolution. Adeno-associated viruses (AAV) and
lentiviruses are most commonly used [21,27,124].
Preference of viral vector can depend on desired speci-
ficity of expression. AAVs spread farther from the injec-
tion site, due to their small size, and lentiviruses typicallywww.sciencedirect.com infect smaller regions, but can carry larger cargo when
needed. Fine spatial resolution can theoretically be
achieved by encoding elements to ensure proper target-
ing to synapses and other neuronal compartments. Recent
efforts have utilized both c-terminal and n-terminal
domains for this purpose and further developments will
enhance specificity to select neuronal compartments
[12,29,103].
As their name implies, genetically targeted technologies
gain resolution through genetic identity. Lentiviruses
have larger packaging capabilities, permitting the use
of transcriptional promoters to target expression neuronal
types, an approach usually not available with AAVs [125].
Cell-type specific promoters, however, may not a drive
sufficient amount of expression [126]. To overcome this,
viruses dependent on DNA recombination, especially
through Cre recombinase, have been developed [127].
Recombinases usually are driven by cell-type specific
promoters in the genome of a transgenic line or in an
independent virus [128]. More discrete populations of
neurons can be targeted using intersectional approaches,
utilizing other recombinases such as FLP and DRE
[129,130]. Recombinase technology can also target neu-
rons that project to the injection site through the use of
Canine-adenovirus (CAV) [131]. CAV viruses have the
ability to infect neurons through retrograde axonal trans-
port [132]. DREADDs have been successfully expressed
in vivo through this method [133,134]. Another, very
promising retro-AAV (rAAV2) was recently developed,
that will open even more possibilities for retrograde
expression [135]. Finally, recombinases are also subject
to optogenetic stimulation, photoactivatable Cre-recom-
binase is continually being optimized for the spatial
control gene regulation in vivo [136–138]. These
approaches of expression allow for further control of
discrete cell type manipulations within neural circuits
offering even greater specificity and reductionism of
neuromodulator pathways in vitro and in vivo.
Development
There are many unexplored avenues of optogenetic and
chemogenetic tool development. These techniques can
be developed to model other GPCR signaling compo-
nents, such as the G11/12 signaling family. Additionally,
the spatial resolution of DREADDs would significantly
increase with photoactivatable ligands. Tuning and op-
timization through mutation can also allow for the devel-
opment of new tools with different signaling dynamics,
including signaling bias, kinetics, spectral properties and
subcellular localization [21,139]. Many optogenetic
tools are still in the conceptual stages and have yet to
be optimized for expression in neurons or in vivo. In a
recent proof of concept report, light induced secretion
was developed using UV8R, a plant photoreceptor [140].
Impressively, the authors used this method to optically
induce secretion of a reporter protein at specific dendriticCurrent Opinion in Pharmacology 2017, 32:56–70
66 Neurosciencesbranch points [140]. Validating this approach with func-
tional signaling proteins will significantly expand the
neuroscience optogenetic toolbox for GPCRs. Full char-
acterization of existing tools and their ability to simulate
endogenous in vivo signaling will be crucial as subcellular
localization and cell-type specific expression can define
GPCR bias in vivo. Overall, in vitro and in vivo validation
of current optogenetic tools will aid the community in
selecting the most applicable tools [141].
Developing advances in many fronts of biological tech-
nology will foster the creation of many genetically tar-
geted approaches. Genome sequencing has dramatically
increased the diversification of the available library of
genomic sequences from biological organisms. Currently,
tens of thousands of sequences for opsins and photoacti-
vatable proteins have been reported [10]. Natural pro-
teins hold potential as resources for opsin based tools with
unique spectral properties with minimal mutagenesis
[10]. Advances in technology, such as 2-photon stimula-
tion and imaging have revitalized the development of
optogenetic tools sensitive to short wavelengths, such as
the recently discovered bistable vertebrate Gi coupled
neuropsin [142]. Structural biology, through high resolu-
tion crystal structures and developing modeling software
will continue to inspire the development of optogenetic
and chemogenetic tools far into the foreseeable future.
Concluding remarks
Optogenetics and chemogenetics have revolutionized the
study of neuronal circuitry and have great potential in
dissecting the role of specific GPCR signaling pathways.
Multiplexing within or between tools enables bidirec-
tional neuromodulatory control of signaling pathways in a
single neuronal population. In addition, multiplexing of
optogenetic actuators and reporters of different spectral
occupancy can further define pre- and post-synaptic sig-
naling involved in behavior and disease states. These
tools also have translational potential, providing reduc-
tionist approaches for understanding drugable neural
circuits that may lead to novel chemical entities for drug
discovery.
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